COVID-19 and Inflammatory Bowel Diseases: Risk Assessment, Shared Molecular Pathways, and Therapeutic Challenges.

Iolanda Valentina Popa Mircea Diculescu Cătălina MihaiCristina Cijevschi-PrelipceanAlexandru Burlacu

Published in: Gastroenterology research and practice (2020)

Using the current understanding of SARS-CoV-2 as well as other pathogenic coronaviruses immunopathology, we showed why IBD patients should not be considered at an increased risk of infection or more severe outcomes. Whether our findings are entirely applicable to the pathogenesis, disease susceptibility, and treatment management of SARS-CoV-2 infection in IBD must be further explored.

Keyphrases

sars cov
respiratory syndrome coronavirus
risk assessment
end stage renal disease
coronavirus disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
type diabetes
ulcerative colitis
metabolic syndrome
early onset
replacement therapy
drug induced
smoking cessation